53.67
Real-Time Quote
 +0.24 / +0.45%
Today’s Change
42.25
Today|||52-Week Range
58.27
+1.63%
Year-to-Date
Pfizer refuses to rule out tax inversion deals
11:03am / FT.com
Why Corporate Inversion Is More Than a Political Punching Bag
Jul 23 / TheStreet.com
Windstream soars on Reit spin-off plan
Jul 29 / FT.com
Healthcare Spending Uptrend: 3 Medical Stocks for Strong Growth - Analyst Blog
Jul 23 / Zacks.com
Pfizer Beats on Q2 Earnings, Revs Despite Generic Pressures - Analyst Blog
Jul 29 / Zacks.com
Johnson & Johnson Announces $5B Share Buyback - Analyst Blog
Jul 22 / Zacks.com
Novo Nordisk Diabetes Drug Xultophy Gets Positive CHMP View - Analyst Blog
Jul 29 / Zacks.com
Allergan, a Valeant Takeover Target, Plans 1,500 Job Cuts - Analyst Blog
Jul 22 / Zacks.com
Novartis Division Gets European Approval for Simbrinza - Analyst Blog
Jul 28 / Zacks.com
3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call
Jul 22 / MotleyFool.com
Markets Little Changed Ahead Of The Federal Reserve's Policy Decision
Jul 28 / Benzinga
3 Quotes From Johnson & Johnson's Conference Call You Need to Read
Jul 22 / MotleyFool.com
Consumer and pharma groups swap assets
Jul 28 / FT.com
Shire's Q2 Earnings Strong but Overshadowed by AbbVie Deal - Analyst Blog
Jul 22 / Zacks.com
Hospira Eyeing Bid For Danone Unit in Latest Tax Deal
Jul 28 / TheStreet.com
Here's What You Need to Know About AbbVie and GlaxoSmithKline's Upcoming Earnings
Jul 22 / MotleyFool.com
Will This Analyst Upgrade Help AbbVie (ABBV) Stock Today?
Jul 28 / TheStreet.com
AbbVie Set to Acquire UK-Based Shire in Q4 - Analyst Blog
Jul 21 / Zacks.com
5 Toxic Stocks You Should Sell This Summer
Jul 25 / TheStreet.com
Pfizer's Stock Falls Ill as the Dow Tumbles
Jul 21 / MotleyFool.com
Humira Still Key to AbbVie
Jul 25 / MotleyFool.com
Welcome to Ireland, AbbVie
Jul 21 / MotleyFool.com
Roche's 1H14 Earnings & Revenues Up Y/Y, Outlook Reaffirmed - Analyst Blog
Jul 25 / Zacks.com
Allergan Beats on Q2 Earnings, Ups View & Plans 13% Job Cut - Analyst Blog
Jul 21 / Zacks.com
AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog
Jul 25 / Zacks.com
Monday Links: Excessive Valuations
Jul 21 / StockTwits
How Will AbbVie (ABBV) Stock React To Its Second Quarter Earnings Beat?
Jul 25 / TheStreet.com
With Shire, Did AbbVie Count Its Chickens Before They Hatched?
Jul 18 / MotleyFool.com
Today's Top Health Care Headlines: AbbVie and GlaxoSmithKline
Jul 25 / MotleyFool.com
AbbVie Inc. Wins the Shire
Jul 18 / MotleyFool.com
Stocks: 6 things to know before the open
Jul 25 / CNNMoney.com
Shire chief's $10m 'golden hello' at AbbVie
Jul 18 / FT.com
Shire, ArmaGen Ink Licensing Agreeement for AGT-182 - Analyst Blog
Jul 24 / Zacks.com
What You Need to Know About Johnson & Johnson's Best-Selling Drugs
Jul 18 / MotleyFool.com
Obama call for US corporate tax crackdown
Jul 24 / FT.com
Shire demands assurances in backroom fight over tax inversion
Jul 18 / FT.com
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Jul 24 / Zacks.com
What crisis? U.S. stocks soar
Jul 18 / CNNMoney.com
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Jul 24 / Zacks.com
Today's Top Health Care Stocks to Watch: AbbVie, Gentiva Health Services and Shire
Jul 18 / MotleyFool.com
Will AbbVie (ABBV) Surprise This Earnings Season? - Analyst Blog
Jul 24 / Zacks.com
Drugmaker in $54.7 billion merger aimed at cutting U.S. taxes
Jul 18 / CNNMoney.com
Glaxo (GSK) Slips on Disappointing Q2 Earnings, Cuts View - Analyst Blog
Jul 24 / Zacks.com
AbbVie seals B#32bn takeover of Shire
Jul 18 / FT.com
#PreMarket Primer: Thursday, July 24: Facebook Proves Its Worth
Jul 24 / Benzinga
Stocks: 5 things to know before the open
Jul 18 / CNNMoney.com
Gilead Stock's Great Expectations and Giant Opportunity
Jul 23 / MotleyFool.com
Banks lead broad FTSE 100 losses
Jul 18 / FT.com
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst...
Jul 23 / Zacks.com
Repros Gets Additional FDA Guidance for Androxal - Analyst Blog
Jul 17 / Zacks.com

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.